Allow the interviewee time to list out the factors that would impact the market size.
For countries with growing population
Population between 0-19 years (20 year time span) = 2 * x + 2 * x
Population between 0-19 years (20 year time span) = 4 * 30 = 120 m
Population between 2-16 years (15 year time span) = 120 m/ 20 * 15
Population between 2-16 years (15 year time span) = 90 m
For countries with declining population
Population between 0-19 years (20 year time span) = 0.75 * y + 0.75 * y
Population between 0-19 years (20 year time span) = 1.5 * 50 = 75 m
Population between 2-16 years (15 year time span) = 75 m/ 20 * 15
Population between 2-16 years (15 year time span) = 56.25 m
Total population between 2-16 years = 90 m + 56.25 m
Total population between 2-16 years = 146.25 mKey insight
The total potential market for the vaccine in Europe would be ~150 m (146.25 m) customers.
2. Sales Forecast for Year 1
What would be the expected sales of the vaccine in year 1?
Allow the interviewee to list out the factors which would affect the sales like competition, percentage of customers likely to purchase the vaccine, government policies affecting uptake, etc.
Information that can be shared if enquired:
- Currently, none of the other pharmaceutical companies have a similar product.
- The vaccine is administered in 3 doses at 6 month intervals. All the three doses together costs 100 € for the patient.
- This course of the vaccine protects the children throughout their lifetime.
- The customer pays after each dose is administered. However, the company plans to launch a pre-paid program for the doses in the subsequent years in order to encourage parents to take all three doses. The vaccine is not effective if only 2 doses are administered.
- Although there are differences in purchasing power of customers across the various countries, for the purpose of this case it is assumed to be uniform. Therefore, the purchasing behavior would be similar across countries.
Share Exhibit 5 if the interviewee enquires about the average cost of treatment of the disease.
Exhibit 5: Comparison of treatment costs
Below would be some of the key inferences from the information shared:
- The information given about the probability of the disease occurring and the treatment cost would give an indication about the likelihood of purchase of the vaccine.
- Since the incidence of the disease is higher at younger ages, it would be a sound assumption to make that the parents of the younger children are more likely to purchase the vaccine.
If the candidate asks for information about the percentage of families with children who would buy the medicine, ask him/her to make a guesstimate backed by logic.
For this solution, we have assumed that the probability of the incidence of the disease can be a proxy for the percentage of customers who will buy the vaccine. However, any other assumption, backed by logic would also be correct.
No. of customers - 2 to 6 years age bracket:
Customers = 150 m / 15 * 5 * 45% = 22. 5 m
No. of customers - 7 to 11 years age bracket:
Customers = 150 m / 15 * 5 * 35% = 17. 5 m
No. of customers - 12 to 16 years age bracket:
Customers = 150 m / 15 * 5 * 10% = 5 m
Total customers = 22.5 m + 17.5 m + 5 m = 45 m
Total Sales = 45 m * 100 € €
A critical factor to crack this case, would be then take into account the vaccination schedule. The above number assumes that all the three doses are administered; however in the first year only 2 of those doses would have be administered. If the interviewee misses this step, prompt him/ her.
Sales in Year 1 = 4.5 B € * 2/3 = 3 B €
At this point, prompt the candidate to also calculate the sales after the initial launch and once the market stabilizes.
The key point to keep in mind is that once all the children (who are likely to purchase the vaccine) in the initial years have been covered, the new sales would come from children who turn 2, as all the older children would have already been covered under the vaccination program.
The number of children who turn 2 ( assuming the birth rates remain unchanged) can be calculated as follows:
New customers = 150 m * 1 year / 15 years
New customers = 10 m
Assuming that the incidence pattern of the disease remains unchanged and therefore only 45% of the parents are willing to buy the vaccine:
Customers = 45% * 10 m = 4.5 m
Sales = 4.5 m * 100 € = 450 m €
For the above calculation, the fact that only 2 doses are administered per year is irrelevant. This is because each year, the children entering the 2 year age bracket are likely to receive the 2 doses, and the children who have already received 2 doses in the previous year, they will receive the third dose. We have also assumed that no parents will pay for all three doses upfront.
3. Conclusion
The candidate must now succinctly lay out the conclusion:
- The total potential number of customers is ~150 m
- The incidence of the disease is higher in younger children and steadily reduces. Therefore, it is likely that a higher percentage of children in the younger age brackets are likely to be vaccinated
- Given the incidence pattern of the disease, about 45 m children are estimated to be the potential customers in Year 1
- As only two doses are administered in Year 1, this would amount to a sale of 3 B €
- After a few years, the sales would stabilize at 450 m €